linjc16/ctgov huggingface dataset:
Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.

Study Overview
=================
Brief Summary
-----------------
It was the aim of the present study to prospectively compare the functional and morphological outcome of idiopathic epiretinal membrane surgery with and without the assistance of Indocyanine green (ICG). The main outcome measure was improvement of best-corrected visual acuity (BCVA). This was treated as an open question and we had no hypothesis which of the two therapies was superior.

Official Title
-----------------
Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial

Conditions
-----------------
Idiopathic Epiretinal Membrane, Cataract

Intervention / Treatment
-----------------
* Drug: Surgery with and without the aid of Indocyanine Green (ICG)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with IEM and cataract or posterior chamber intraocular lens pseudophakia complaining of loss of visual acuity and metamorphopsia during the past six months. Exclusion Criteria: Other retinal disease, non-idiopathic epiretinal membrane, glaucoma or history of retinal detachment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Surgery with and without the aid of Indocyanine Green (ICG)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The main outcome measure was improvement of best-corrected visual acuity (BCVA). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other outcome measures included postoperative BCVA, status of Amsler grid test, reduction of macular retinal thickness, residual or recurrent macular epiretinal membrane |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Indocyanine green, toxicity, epiretinal membrane, visual field defect
Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
There is a possible implication of sleep apnea syndrome via night-time intermittent hypoxemia in perturbation of quality of life and tumour progression to patients with a bronchial cancer. The aim of the study is to evaluate this possibility with the help of a night record of sleep and quality of life questionnaires.

Detailed Description
-----------------
There is a possible implication of sleep apnea syndrome via night-time intermittent hypoxemia in perturbation of quality of life and tumour progression to patients with a bronchial cancer. Enrollment 1200 patients This wide sample is expected to respond to the main and secondary objectives of the study

Official Title
-----------------
Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer

Conditions
-----------------
Bronchial Cancer

Intervention / Treatment
-----------------
* Device: With and without SDB


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with NSCLC undergoing diagnostic Performance status 0,1,2 Exclusion Criteria: >75 years OSA known and in the last 12 months treated PS >2 Patients under a long-term oxygen therapy persons deprived of liberty by judicial decision. <18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: With and without SDB<br>comparison of patients with and without sleep-disordered breathing | Device: With and without SDB<br>* Screening of sleep-disordered breathing (SDB)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxygen desaturation index | RECORDING BY POLYGRAPHY DEVICE between day 1 and day 15 after enrollment | Between day 1 and day 15 |
Use of Ketamine Prior to Cardiopulmonary Bypass in Children

Study Overview
=================
Brief Summary
-----------------
To assess whether the drug ketamine given prior to cardiopulmonary bypass can decrease injury to the cells in the brain.

Official Title
-----------------
Use of Ketamine Prior to Cardiopulmonary Bypass in Children

Conditions
-----------------
Ventricular Septal Defect

Intervention / Treatment
-----------------
* Drug: saline
* Drug: ketamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: less than one year of age undergoing cardiac surgery for repair of ventricular septal defect requiring cardiopulmonary bypass not requiring retrogrades cerebral perfusion Exclusion Criteria: Downs Syndrome

Ages Eligible for Study
-----------------
Maximum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: 1<br> | Drug: saline<br>* 2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass<br>|
| Experimental: 2<br> | Drug: ketamine<br>* 2 mg/Kg IV within 5 minutes of cardiopulmonary bypass<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare expression of serum markers of CNS injury |  | within 48 hours | 
| to compare expression of multiple pro and anti-inflammatory cytokines between cases and controls. |  | within 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to compare the clinical, radiological and neurodevelopmental outcomes of the cases and controls |  | one month |
Second Trimester Labor Induction

Study Overview
=================
Brief Summary
-----------------
A superior second trimester medical abortion regimen has not been identified. Studies suggest that a regimen of mifepristone and misoprostol given 36 to 48 hours apart has the shortest median induction-to-abortion interval, highest 24-hour abortion rate, and low rates of adverse events. Narrowing the interval between the two medications without clinically reducing effectiveness may increase access and acceptability for patients and reduce costs. Data from studies on first trimester abortions suggest that the 6 to 8 hour interval between mifepristone and misoprostol is as efficacious as the 36 to 48 hour interval. There are no studies on shorter intervals with same day administration between mifepristone and misoprostol in second trimester abortions. The primary objective is to assess the efficacy of the combined mifepristone/misoprostol regimen for abortions between 17 0/7 and 23 6/7 weeks' gestation using an interval of 6 to 8 hours between the two medications.

Official Title
-----------------
A Pilot Study of Mifepristone Followed by Misoprostol in Women Undergoing Second Trimester Abortion

Conditions
-----------------
Second Trimester Labor Induction

Intervention / Treatment
-----------------
* Drug: Experimental (mifepristone and misoprostol)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: English-speaking women 18 years of age and above Voluntarily choose to undergo pregnancy termination via labor induction An ultrasound-confirmed singleton intrauterine pregnancy between 17 0/7 and 23 6/7 weeks gestation Able to provide written consent Exclusion Criteria: Premature rupture of membranes Preterm labor Intrauterine fetal demise Chronic systemic corticosteroid use or adrenal disease Hypersensitivity to prostaglandins Cardiovascular disease such as angina, valvular disease, arrhythmia, cardiac failure Known coagulopathy or treatment with anticoagulants Prior caesarean delivery or myomectomy Placenta previa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br>Mifepristone followed by labor induction with misoprostol after 6-8 hours | Drug: Experimental (mifepristone and misoprostol)<br>* Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Abortion rate |  | 8 hours after misoprostol administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Second trimester labor induction
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Study Overview
=================
Brief Summary
-----------------
To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Official Title
-----------------
Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.

Conditions
-----------------
Escherichia Coli Infections, Klebsiella Infections

Intervention / Treatment
-----------------
* Drug: vancomycin-resistant enterococci and ESBL


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients admitted to or transferred to the MICU. Patients 18 years of age or older. Provide written informed consent. Exclusion Criteria: Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae. Patients who have hypersensitivity to penicillin. Any underlying conditions or diseases that will be ultimately fatal within 48 hours. Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: vancomycin-resistant enterococci and ESBL|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bacterial Infections
ICU Mortality Predictors of Trauma Patients

Study Overview
=================
Brief Summary
-----------------
In this study, the data of the patients who were hospitalized due to trauma in intensive care unit (ICU) were examined in their first development. The mortality rate and the factors affecting mortality in these patients were determined

Detailed Description
-----------------
In this study, 107 trauma patients were examined. Patients were divided into two groups according to ICU results: survivors (Group 1) and deceased patients (Group2). Patients were rated in terms of age, Neutrophil lymphocyte ratio (NLR) , mean platelet volüme (MPV), lactat value, intensive care unit stay, APACHE 2 soring systems. Mortality rate and the factors affecting this rate were examined. 83 of the patients were male (77.58%) and 24 were female (22.42%). The mean age was 46 years. The mean value of lactate level was 3.25. MPV mean value was 10.34. NLR mean value was 8.23 and Apache 2 score mean value was 22.8. The average length of stay in hospital was 11.33 days. When the intergroup mortality was evaluated in terms of the relationship between continuous variables, there was a statistically significant difference in apache 2 score. No statistically significant difference was found between age, lactate, MPV, NRL and length of hospital stay. NRL, MPV, Lactate levels were not suitable for evaluation of trauma patients as a early prognostic factor in the first day ICU admission. The investigators think that the use of trauma scoring systems such as apache 2 related to mortality during first hospitalization in ICU is more appropriate.

Official Title
-----------------
Prognostic Effect of Neutrophil \ Lymphocyte Ratio, Lactate Level and Apache 2 Score on Mortality in Intensive Care Trauma Patients at First Hospitalizations

Conditions
-----------------
İntensive Care Unit

Intervention / Treatment
-----------------
* Other: decesased patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: trauvma patients Exclusion Criteria: systemic inflammatory diseases cancer renal failure cardiac failure serebro vascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| living patients<br>living patients in intersivecare unit about 28 days | Other: decesased patients<br>* mortality ratio<br>|
| deceased patients<br>deceased patients in intersivecare unit about 28 days | Other: decesased patients<br>* mortality ratio<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortallty | mortallty ratio | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trauma, mortality
Real World Data Collection and Analysis on the Anterior Cervical Spine Surgery

Study Overview
=================
Brief Summary
-----------------
This observational study aims to evaluate the efficacy and safety of anterior cervical spine surgery in patients with cervical degenerative disc disease

Detailed Description
-----------------
This observational study is an ambispective cohort designed. Patients who are diagnosed cervical degenerative disc disease will be selected to join in this study. Visual Analogue Scale, Japanese Orthopaedic Association Scale, Neck Disability Index, SF-36, and device related or procedure related adverse events will be recorded and compared to evaluate the efficacy and safety of anterior cervical spine surgery in patients with cervical degenerative disc disease

Official Title
-----------------
Efficacy and Safety of Anterior Cervical Spine Surgery in Patients With Cervical Degenerative Disc Disease - a Real World Data Collection and Analysis Study

Conditions
-----------------
Cervical Disc Degeneration

Intervention / Treatment
-----------------
* Other: Collection Data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years old Clinical symptoms and imaging support cervical degenerative disc disease； Failed a minimum of 3months conservative treatment Have had (retrospective cohort) or the decision has been made to have (prospective cohort) anterior cervical spine surgery Written informed consent given by subject Exclusion Criteria: Patients with non-degenerative (e.g., trauma, tumor, and infection) or neuromuscular diseases (e.g., motor neuron disease) were excluded Patients with cervical spine X-ray film and CT scan contraindications Women who are lactating and pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Collection Data|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Japanese Orthopaedic Association Scale | Establishing criteria for mild, moderate and severe impairment in patients with degenerative cervical myelopathy. The minimum value is 0, and the maximum value is 17. Higher scores mean a better outcome. | 1st year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck Disability Index | The index to evaluate the neck pain and life quality. The minimum value is 0%, and the maximum value is 100%. Higher scores mean a worse outcome. | 1st year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical Degenerative Disease, Cervical Myelopathy, Cervical Radiculopathy, Anterior Cervical Spine Surgery
Efficacy of Intra-articular NSAID Versus Corticosteroid in the Treatment of Shoulder and Knee Conditions: A Randomized, Double-Blind, Prospective Study

Study Overview
=================
Brief Summary
-----------------
The proposed study will compare the efficacy of Triamcinolone versus Ketorolac for intra-articular injection of the knee and shoulder

Detailed Description
-----------------
This study will be a randomized prospective study comparing Triamcinolone to Ketorolac for injections in the knee and shoulder for a variety of orthopedic conditions. The investigators will monitor pain relief, length of pain relief, cost, and patient satisfaction after the injections

Official Title
-----------------
Efficacy of Intra-articular NSAID Versus Corticosteroid in the Treatment of Shoulder and Knee Conditions: A Randomized, Double-Blind, Prospective Study

Conditions
-----------------
Knee Arthritis, Shoulder Arthritis, Shoulder Impingement, Meniscus Lesion, Rotator Cuff Tear, Rotator Cuff Tear Arthropathy

Intervention / Treatment
-----------------
* Drug: Shoulder injection
* Drug: knee injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: knee and shoulder arthritis shoulder impingement rotator cuff tear Exclusion Criteria: chronic pain management allergy to NSAIDs or steroids prior surgery kidney disease that would preclude NSAID administration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ketorolac<br> | Drug: Shoulder injection<br>* intra articular or subacromial shoulder injection<br>Drug: knee injection<br>* intra-articular knee injection<br>|
| Experimental: Kenalog<br> | Drug: Shoulder injection<br>* intra articular or subacromial shoulder injection<br>Drug: knee injection<br>* intra-articular knee injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain level: VAS score | VAS score | 0-6 months | 
| length pain relief | length of time patient reports pain relief | 0-6 months |
Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients

Study Overview
=================
Brief Summary
-----------------
Low habitual intake of low-dose dark chocolate (6 g/day) has been shown to have a beneficial effect on arterial blood pressure in one previous study. The trial will assess if ingestion of a higher but still moderate dose (25 g/day) over 3 months will have a more pronounced effect. The population will consist of cardiovascular high-risk patients only (who will potentially benefit most from blood-pressure lowering).

Official Title
-----------------
Effect of Different Dosages of Dark Chocolate on Arterial Blood Pressure in Cardiovascular High-risk Patients

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Dietary Supplement: dark chocolate 6 g/day
* Dietary Supplement: dark chocolate 25 g/day


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years mean ambulatory blood pressure 125-146 mmHg and/or 80-89 mmHg high cardiovascular risk profile (one or more of the following: CAD, PAD, carotid stenosis, diabetes) informed consent Exclusion Criteria: habituary intake of dark chocolate or cocoa products mean ambulatory blood pressure 147 mmHg or greater and/or 90 mmHg or greater pregnancy uncontrolled diabetes severe comorbidity change in blood pressure medication within last 6 weeks participation in another trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>dark chocolate 6 g/day | Dietary Supplement: dark chocolate 6 g/day<br>* dark chocolate 6 g/day<br>|
| Active Comparator: 2<br>dark chocolate 25 g/day | Dietary Supplement: dark chocolate 25 g/day<br>* dark chocolate 25 g/day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in mean ambulatory arterial blood pressure |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in weight and BMI |  | 3 months | 
| change in various lab parameters |  | 3 months |